Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases - Top-Institutions - MDSpire

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

  • By

  • Zhipeng Fan

  • Peikai Sun

  • Lei Li

  • July 6, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Vanderbilt-Ingram Cancer Center
    Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

    Key Differentiators

    • Oncology

  • #5

    Massachusetts General Hospital Cancer Center
    Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

  • by Zhipeng Fan, Peikai Sun, Lei Li

  • July 6, 2026

Related Content

Identification of potential vinorelbine-associated prognostic genes in breast cancer through integrative bioinformatics and experimental validation

Metastatic malignant melanoma presenting as bilateral acute mastitis in a lactating woman: a case report and literature review

Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk